𝐇𝐨𝐰 𝐦𝐲 𝐟𝐚𝐭𝐡𝐞𝐫 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐞𝐝 𝐬𝐲𝐦𝐩𝐭𝐨𝐦𝐬 𝐨𝐟 𝐌𝐄/𝐂𝐅𝐒 𝐚𝐧𝐝 𝐋𝐨𝐧𝐠 𝐂𝐎𝐕𝐈𝐃 𝐚𝐟𝐭𝐞𝐫 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐰𝐢𝐭𝐡 𝐈𝐂𝐈𝐬
When I wrote the article comparing ME/CFS and Long COVID with the symptoms developed by some patients treated with ICIs who carry HLA-II susceptible alleles, I never imagined that my father would later receive the same treatment to cope with the cancer he has developed.
After several doses of Immune checkpoint inhibitors (ICIs), my father began to experience fatigue, dysautonomia, diarrhea, dysphagia, bloating, cognitive impairment, slowed thinking and speech, nasal congestion, runny nose, post-exertional fatigue, among other symptoms. It is as if the ICIs “recreate” the characteristic symptoms of ME or Long COVID by inducing immune hyperactivity and increasing the risk of developing autoimmunity in patients with susceptible HLA-II alleles.
Observing these symptoms, we suggested to the physician to check his cortisol levels. To our surprise, it was confirmed that he had developed hypocortisolism, something I had feared since I learned that he also carries the HLA-DR15 allele, as do I, who am homozygous for that variant. After the diagnosis of hypocortisolism, he was prescribed hydrocortisone replacement therapy, and in just 24 hours, his symptoms disappeared, leaving only some fatigue at night.
In my case, after my hospitalization in 2013, I also received cortisol replacement therapy due to my extremely low ACTH and cortisol levels, in addition to inflammation in the adenohypophysis detected by MRI. However, after a year of treatment, it was withdrawn because morning cortisol tests apparently showed normal levels. As I have discussed in another post, a single morning test does not give a complete picture of the circadian cortisol rhythm. Since then, I have not gone back on hydrocortisone, believing that my only problem was chronic EBV infection.
Unfortunately, I know of very few patients who have had their cortisol levels tested and had a pituitary MRI in the early stages of their symptoms. In my case, the HLA-DR15 allele made me vulnerable to EBV infection, resulting in a failure to control infected cells, causing chronic immune hyperactivity due to the constant presence of viral antigens. In my father's case, therapy with ICIs triggered immune hyperactivity by inhibiting immune checkpoints, allowing the immune system to attack healthy tissues and generate autoimmunity, with autoimmune hypophysitis being one of the most common manifestations. However, not all patients treated with ICIs develop these autoimmune diseases, and it has been linked primarily to those who carry certain susceptible HLA-II alleles, such as HLA-DR15.
Therefore, both my father and I, sharing the HLA-DR15 allele, have a genetic susceptibility that leads to an exaggerated hyperresponsiveness to certain specific antigens. In my father, this hyperactivation was induced by treatment, whereas in my case it was a consequence of infection. I do not know the other HLA-II allele that my father carries, but since I am homozygous for HLA-DR15, it is possible that I am at greater risk for this hyperactivation, as the two HLA-II alleles that we both carry are co-expressed. The difference is that, if there has been no significant damage to my father's pituitary, he could regain normal ACTH secretion after stopping treatment. In my case, as the chronic infection that triggers hyperactivation and autoimmunity against the pituitary persists, the problem will continue.
Having said all of the above, it is important to note that many patients with ME/CFS or Long COVID might think that with hydrocortisone replacement therapy alone they should get better from all symptoms, and this is not the case. This is evident in both my father and other patients treated with ICIs, as these patients do not face the other consequences caused by a chronic infection. Therefore, patients with ME/CFS and Long COVID who have permanent pituitary damage, in addition to receiving hydrocortisone replacement doses, should also consider antiviral treatment to prevent viral reactivation and reduce the viral reservoirs responsible for their immune hyperactivation and autoimmunity.
It would be extremely valuable to compare patients treated with ICIs who develop hypophysitis with those with ME/CFS or Long COVID who present with pituitary involvement. Our research group would like to explore this line and analyze other markers related to this pathophysiology, but currently we do not have the necessary funds to carry it out. If you know of any calls for proposals or any organization interested in funding us, we would be grateful if you could let us know. We are also open to collaborate with other centers.
Here is more information about the relationship between ICIs, ME/CFS and Long COVID:
https://x.com/manruipa/status/1826252428213211182
If you found it useful, please share it so that other patients can better understand their disease.